Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial-Reference-Cited by-同舟云学术

Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: a subgroup analysis of the SAVE-MORE randomised trial

Published:2023-02 Issue: Volume:56 Page:101785
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Akinosoglou Karolina^ORCID,Kotsaki Antigone,Gounaridi Ioanna-Maria^ORCID,Christaki Eirini,Metallidis Simeon,Adamis Georgios,Fragkou Archontoula,Fantoni Massimo,Rapti Aggeliki,Kalomenidis Ioannis,Chrysos Georgios,Boni Gloria,Kainis Ilias,Alexiou Zoi,Castelli Francesco,Serino Francesco Saverio,Bakakos Petros,Nicastri Emanuele,Tzavara Vassiliki,Safarika Asimina^ORCID,Ioannou Sofia,Dagna Lorenzo,Dimakou Katerina,Tzatzagou Glykeria,Chini Maria,Bassetti Matteo,Kotsis Vasileios,Angheben Andrea,Tsoukalas George,Selmi Carlo,Spiropoulou Olga-Maria,Samarkos Michael,Doumas Michael,Damoraki Georgia,Masgala Aikaterini,Papanikolaou Ilias,Argyraki Aikaterini,Negri Marcantonio^ORCID,Leventogiannis Konstantinos,Sympardi Styliani,Gatselis Nikolaos K.,Petrakis Vasileios,Netea Mihai G.,Panagopoulos Periklis,Sakka Vissaria^ORCID,Milionis Haralampos,Dalekos George N.,Giamarellos-Bourboulis Evangelos J.^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference18 articles.

1. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia;Rovina;Crit Care,2020

2. IL-1 mediates tissue specific inflammation and severe respiratory failure in COVID-19;Renieris;J Innate Immun,2022

3. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial;Kyriazopoulou;Nat Med,2021

4. An open label trial of anakinra to prevent respiratory failure in COVID-19;Kyriazopoulou;Elife,2021

5. Longitudinal analyses reveal immunological misfiring in severe COVID-19;Lucas;Nature,2020

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune‐mediated inflammatory diseases as long‐term sepsis complications: Long‐term persistence of host dysregulation?;Journal of Internal Medicine;2023-12-13

2. Adjuvante Behandlung bei COVID-19 und Sepsis − was haben wir gelernt?;Medizinische Klinik - Intensivmedizin und Notfallmedizin;2023-11-15

3. Calprotectin serum levels on admission and during follow-up predict severity and outcome of patients with COVID-19: A prospective study;European Journal of Internal Medicine;2023-11

4. Anakinra authorized to treat severe coronavirus disease 2019; Sepsis breakthrough or time to reflect?;Frontiers in Microbiology;2023-10-19

5. Biomarkers to guide immunomodulatory treatment: where do we stand?;Expert Review of Molecular Diagnostics;2023-09-20